The remarkable reliance of PCa on AR signalling led to the generation of effective targeted therapies, such as enzalutamide, abiraterone acetate and other small molecule inhibitors of the AR pathway, which have significantly improved the clinical management of non‐resectable prostate tumours. This evidence concerns the gene AR and posterior cortical atrophy.